Menovo(SH:603538) Sou Hu Cai Jing·2025-08-19 07:57Core Viewpoint - Meinuo Pharma (603538) has shown a positive performance in the stock market with a closing price of 29.03 yuan, reflecting a 1.93% increase as of August 19, 2025 [1] Financial Performance - The latest quarterly report indicates total revenue of 276 million yuan, representing a year-on-year growth of 5.22% [1] - The net profit attributable to shareholders reached 21.22 million yuan, marking a significant year-on-year increase of 51.12% [1] - The non-recurring net profit was reported at 16.62 million yuan, which is a decrease of 19.02% compared to the previous year [1] - Key financial ratios include a current ratio of 1.206, a quick ratio of 0.651, and a debt-to-asset ratio of 50.05% [1] Market Activity - The stock experienced a trading volume of 417,000 hands and a transaction amount of 1.238 billion yuan [1] - The net inflow of main funds was 68.96 million yuan, accounting for 5.57% of the total transaction amount [1] - Large orders contributed to a net inflow of 46.90 million yuan, while small orders saw a net outflow of 45.94 million yuan [1] Company Background - Meinuo Pharma, established in 2004 and located in Ningbo, primarily engages in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 2.198 billion yuan and a paid-in capital of 900 million yuan [1][2] - The legal representative of the company is Yao Chengzhi [1] Investment and Intellectual Property - Meinuo Pharma has made investments in 16 external enterprises and participated in 6 bidding projects [2] - The company holds 1 trademark and 27 patents, along with 9 administrative licenses [2]